| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 8, 2022Virtual Press Office and PR Newswire: General Trade show news
- Combining onvansertib with the PARP inhibitor (PARPi) olaparib led to statistically significant survival benefits compared to treatment with either agent alone in PARPi-resistant ovarian cancer...
-
Apr 8, 2022Virtual Press Office and PR Newswire: General Trade show news
Trial evaluates onvansertib in combination with abiraterone and prednisone in metastatic castration-resistant prostate cancer (mCRPC) patients showing initial abiraterone resistance by rising PSA...
-
Apr 8, 2022New Data at AACR Showcase Reaction Biology's Innovative Approach to Oncology Drug Discovery ServicesVirtual Press Office and PR Newswire: General Trade show news
~ New diacylglycerol kinase assay panel provides researchers for the first time with ten new lipid kinase targets ~ ~ New systems biology approach enhances preclinical characterization of the...
-
Apr 8, 2022Virtual Press Office and PR Newswire: General Trade show news
-- Early dose escalation data show dose-dependent reductions in ctDNA and tumor burden -- -- Generally well-tolerated with most AEs Grade 1 or 2, supporting continued dose escalation -- --...
-
Apr 8, 2022Virtual Press Office and PR Newswire: General Trade show news
Results from Phase 1 Dose Escalation Study of Tegavivint in Patients with Desmoid Tumors to Be Featured as in a Poster Presentation on April 12, 2022 HOUSTON, April 8, 2022 /PRNewswire/ -- Iterion...
